Skip to main content
NVCR
NASDAQ Industrial Applications And Services

NovoCure Q2 Revenue Jumps 16%, Adjusted EBITDA Turns Positive, but TRIDENT Trial Misses Primary Endpoint

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$16.23
Mkt Cap
$1.803B
52W Low
$9.82
52W High
$18.92
52W Position info
65% above low
Off High info
14% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NVCR sits 65% above its 52-week low of $9.82.

Summary

NovoCure's Q2 2026 revenue grew 16% to $183.6M, Adjusted EBITDA turned positive at $10.8M, and the Optune Pax launch added 285 patients. However, the Phase 3 TRIDENT trial in GBM failed to meet its primary endpoint, removing a major growth driver.


Key Events · Earnings and Guidance · NVCR

  • Revenue Growth Accelerates

    Q2 2026 net revenues rose 16% YoY to $183.6M, driven by 18% active patient growth to 5,128. U.S. revenue grew 9% to $103.0M, while international markets surged 25% to $74.7M.

  • Adjusted EBITDA Turns Positive

    Adjusted EBITDA swung to a gain of $10.8M from a loss of $9.9M in Q2 2025, reflecting revenue growth, cost efficiencies, and a $4.9M tariff refund. Net loss narrowed to $15.7M from $40.1M.

  • TRIDENT Trial Misses Primary Endpoint

    The Phase 3 TRIDENT trial evaluating earlier initiation of TTFields therapy in newly diagnosed GBM failed to show a statistically significant improvement in overall survival (median OS 17.7 vs 17.5 months, HR 0.953, p=0.519).

  • Optune Pax Launch Gains Traction

    Optune Pax for pancreatic cancer contributed $1.6M in revenue and 285 active patients in its first full quarter post-FDA approval. The company also received CE Mark approval for the same indication.


Analysis · NVCR · Industrial Applications And Services

NovoCure delivered strong commercial execution with 18% active patient growth and a swing to positive Adjusted EBITDA, but the Phase 3 TRIDENT trial failure in newly diagnosed GBM removes a key near-term catalyst. The Optune Pax launch is off to a promising start with 285 active patients and $1.6M in revenue. Cash remains robust at $440.6M, though the company acknowledges it may need to raise additional capital as it expands into new indications. The mixed quarter — operational momentum offset by a clinical setback — keeps the investment thesis in flux.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCR was trading at $16.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $11.72 info
Change: -$2.23 (-16%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $11.72 info
Change: -$2.53 (-18%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $11.72 info
Change: -$3.62 (-24%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $11.72 info
Change: -$2.53 (-18%) info
Market Cap: $1.321B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $11.72 info
Change: -$4.34 (-27%) info
Market Cap: $1.321B info